TGTX TG Therapeutics
- 26.900
- +1.840+7.34%
- 27.050
- +0.150+0.56%
TG Therapeutics News
TG Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(14.2%)
TG Therapeutics | 10-Q: Q2 2024 Earnings Report
TG Therapeutics | 10-K/A: Annual report (Amendment)
TG Therapeutics | 8-K: ® TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI (ublituximab-xiiy) Full Year Revenue Guidance
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Lonial Sagar
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HUME DANIEL
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hoberman Kenneth
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Echelard Yann
TG Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Charney Laurence N
TG Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
TG Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
TG Therapeutics | 8-K: Current report
TG Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
TG Therapeutics | PX14A6G: Notice of exempt solicitation
TG Therapeutics | PX14A6G: Notice of exempt solicitation
TG Therapeutics | 10-Q: Q1 2024 Earnings Report
TG Therapeutics | 8-K: TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TG Therapeutics | ARS: Annual Report to Security Holders
TG Therapeutics | DEFA14A: Others
TG Therapeutics | DEF 14A: Definitive information statements
Analysis
Price Target
No Data
No Data